{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:50:42Z","timestamp":1768470642402,"version":"3.49.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11899-018-0469-3","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T21:58:43Z","timestamp":1535493523000},"page":"407-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis"],"prefix":"10.1007","volume":"13","author":[{"given":"John H.","family":"Baird","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"\u2022\u2022 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. Revised 2016 World Health Organization classification for mastocytosis, identifying clinical and pathologic diagnostic criteria for disease subtypes","journal-title":"Blood"},{"key":"469_CR2","unstructured":"Horny H-P, Akin C, Arber DA, Peterson LA, Tefferi A, Metcalfe DD. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization (WHO) classification of tumours pathology & genetics tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. p. 61\u201369."},{"issue":"23","key":"469_CR3","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K.-H. Lim","year":"2009","unstructured":"Lim K-H, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727\u201336.","journal-title":"Blood"},{"key":"469_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","volume":"124","author":"L Escribano","year":"2009","unstructured":"Escribano L, Alvarez-Twose I, S\u00e1nchez-Mu\u00f1oz L, Garcia-Montero A, N\u00fa\u00f1ez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514\u201321.","journal-title":"J Allergy Clin Immunol"},{"key":"469_CR5","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","volume":"114","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lim K-H, Lasho TL, Finke C, McClure RF, Li C-Y, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769\u201372.","journal-title":"Blood"},{"key":"469_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","volume":"115","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lim K-H, Lasho TL, Finke CM, McClure RF, Li C-Y, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150\u20131.","journal-title":"Blood"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris M-O, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013;121:1285\u201395.","journal-title":"Blood"},{"key":"469_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","volume":"17","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010;17:125\u201332.","journal-title":"Curr Opin Hematol"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"\u2022\u2022 Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29:1223\u201332. Consensus guidelines on diagnostic testing and therapeutic monitoring of KIT D816 mutant allele burden","journal-title":"Leukemia"},{"issue":"2","key":"469_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","volume":"113","author":"Robert Fritsche-Polanz","year":"2001","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357\u201364.","journal-title":"British Journal of Haematology"},{"issue":"7","key":"469_CR11","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"A. C. Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366\u201372.","journal-title":"Blood"},{"issue":"9","key":"469_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","volume":"24","author":"Laura S\u00e1nchez-Mu\u00f1oz","year":"2011","unstructured":"S\u00e1nchez-Mu\u00f1oz L, Alvarez-Twose I, Garc\u00eda-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol. 2011;24:1157\u201368.","journal-title":"Modern Pathology"},{"issue":"4","key":"469_CR13","doi-asserted-by":"publisher","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","volume":"3","author":"Fanny Lanternier","year":"2008","unstructured":"Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, Zermati Y, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One. 2008;3:e1906.","journal-title":"PLoS ONE"},{"key":"469_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.13567","volume":"172","author":"C M\u00e9ni","year":"2015","unstructured":"M\u00e9ni C, Bruneau J, Georgin-Lavialle S, Le Sach\u00e9 de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642\u201351.","journal-title":"Br J Dermatol"},{"issue":"14","key":"469_CR15","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J. Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136.","journal-title":"Blood"},{"issue":"8","key":"469_CR16","doi-asserted-by":"publisher","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","volume":"7","author":"Fabiola Traina","year":"2012","unstructured":"Traina F, Visconte V, Jankowska AM, Makishima H, O\u2019Keefe CL, Elson P, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One. 2012;7:e43090.","journal-title":"PLoS ONE"},{"key":"469_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.2010.031690","volume":"96","author":"TM Wilson","year":"2011","unstructured":"Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011;96:459\u201363.","journal-title":"Haematologica"},{"issue":"1","key":"469_CR18","doi-asserted-by":"publisher","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","volume":"9","author":"Gandhi Damaj","year":"2014","unstructured":"Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9:e85362.","journal-title":"PLoS ONE"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","volume":"10","author":"K Sotlar","year":"2008","unstructured":"Sotlar K, Bache A, Stellmacher F, B\u00fcltmann B, Valent P, Horny H-P. Systemic mastocytosis associated with chronic idiopathic myelofibrosis. J Mol Diagn. 2008;10:58\u201366.","journal-title":"J Mol Diagn"},{"key":"469_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaci.2012.04.013","volume":"130","author":"S Broesby-Olsen","year":"2012","unstructured":"Broesby-Olsen S, Kristensen TK, M\u00f8ller MB, Bindslev-Jensen C, Vestergaard H, Mastocytosis Centre, Odense University Hospital (MastOUH). Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. J Allergy Clin Immunol. 2012;130:806\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"469_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"\u2022 Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30:136\u201343. First reported NGS data in advSM patients identifying S\/A\/R pos phenotype as adverse prognostic risk factor.","journal-title":"Leukemia"},{"issue":"5","key":"469_CR22","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/leu.2009.37","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Levine RL, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900\u20134.","journal-title":"Leukemia"},{"issue":"24","key":"469_CR23","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","volume":"120","author":"E. Soucie","year":"2012","unstructured":"Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012;120:4846\u20139.","journal-title":"Blood"},{"key":"469_CR24","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/leu.2016.190","volume":"30","author":"M Jawhar","year":"2016","unstructured":"\u2022 Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016;30:2342\u201350. Identification of splenomegaly, elevated alkaline phosphatase, and S\/A\/R gene panel as independent variables predicting OS for SM patients.","journal-title":"Leukemia"},{"key":"469_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ajh.24426","volume":"91","author":"A Pardanani","year":"2016","unstructured":"\u2022 Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, et al. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91:888\u201393. Identification of clinical-molecular MAPSS prognostic scoring system for SM to predict high-risk groups by OS.","journal-title":"Am J Hematol"},{"issue":"5","key":"469_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny H-P, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015;29:1115\u201322.","journal-title":"Leukemia"},{"key":"469_CR27","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1373\/clinchem.2006.068205","volume":"52","author":"A Tan","year":"2006","unstructured":"Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem. 2006;52:2250\u20137.","journal-title":"Clin Chem"},{"key":"469_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","volume":"89","author":"T Kristensen","year":"2012","unstructured":"Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, M\u00f8ller MB, Mastocytosis Centre Odense University Hospital (MastOUH). Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol. 2012;89:42\u20136.","journal-title":"Eur J Haematol"},{"issue":"1","key":"469_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"Philipp Erben","year":"2013","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny H-P, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93:81\u20138.","journal-title":"Annals of Hematology"},{"issue":"6","key":"469_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/all.12409","volume":"69","author":"G. Hoermann","year":"2014","unstructured":"Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69:810\u20133.","journal-title":"Allergy"},{"issue":"10","key":"469_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/all.12436","volume":"69","author":"P. Valent","year":"2014","unstructured":"Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014;69:1267\u201374.","journal-title":"Allergy"},{"key":"469_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.23672","volume":"89","author":"T Kristensen","year":"2014","unstructured":"Kristensen T, Vestergaard H, Bindslev-Jensen C, M\u00f8ller MB, Broesby-Olsen S, Mastocytosis Centre, Odense University Hospital (MastOUH). Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol. 2014;89:493\u20138.","journal-title":"Am J Hematol"},{"issue":"11","key":"469_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","volume":"33","author":"Arturo Vega-Ruiz","year":"2009","unstructured":"Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quint\u00e1s-Cardama A, Luthra R, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33:1481\u20134.","journal-title":"Leukemia Research"},{"key":"469_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D\u2019Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686\u201392.","journal-title":"Exp Hematol"},{"key":"469_CR35","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","volume":"103","author":"C Akin","year":"2004","unstructured":"Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222\u20135.","journal-title":"Blood"},{"key":"469_CR36","first-page":"1115","volume":"1","author":"MJ Frost","year":"2002","unstructured":"Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"469_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","volume":"30","author":"Ling Yan Zhang","year":"2006","unstructured":"Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30:373\u20138.","journal-title":"Leukemia Research"},{"issue":"5","key":"469_CR38","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","volume":"112","author":"K. M. Hoffmann","year":"2008","unstructured":"Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655\u20137.","journal-title":"Blood"},{"key":"469_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","volume":"86","author":"A Mital","year":"2011","unstructured":"Mital A, Piskorz A, Lewandowski K, Was\u0105g B, Limon J, Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol. 2011;86:531\u20135.","journal-title":"Eur J Haematol"},{"issue":"9383","key":"469_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NCP, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535\u20136.","journal-title":"The Lancet"},{"key":"469_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.21996","volume":"107","author":"HJ Droogendijk","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PLA. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107:345\u201351.","journal-title":"Cancer"},{"key":"469_CR42","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","volume":"30","author":"I Alvarez-Twose","year":"2012","unstructured":"Alvarez-Twose I, Gonz\u00e1lez P, Morgado JM, Jara-Acevedo M, S\u00e1nchez-Mu\u00f1oz L, Matito A, et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol. 2012;30:e126\u20139.","journal-title":"J Clin Oncol"},{"key":"469_CR43","doi-asserted-by":"crossref","unstructured":"Huang L, Wang SA, Konoplev S, Bueso-Ramos CE, Thakral B, Miranda RN, et al. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities. Medicine (Baltimore) [Internet]. 2016 [cited 2018 Feb 12];95. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5072932\/ .","DOI":"10.1097\/MD.0000000000004934"},{"key":"469_CR44","doi-asserted-by":"crossref","unstructured":"Alvarez-Twose I, Matito A, Morgado JM, S\u00e1nchez-Mu\u00f1oz L, Jara-Acevedo M, Garc\u00eda-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8:68950\u201363.","DOI":"10.18632\/oncotarget.10711"},{"key":"469_CR45","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","volume":"38","author":"KJ Aichberger","year":"2008","unstructured":"Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Investig. 2008;38:869\u201373.","journal-title":"Eur J Clin Investig"},{"key":"469_CR46","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","volume":"14","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Tefferi A, Cortes J, O\u2019Brien S, Garcia-Manero G, Pardanani A, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14:3906\u201315.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"469_CR47","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","volume":"141","author":"Andreas Hochhaus","year":"2015","unstructured":"Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, M\u00fcller MC, Reiter A, et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015;141:2047\u201360.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"469_CR48","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"M-T Krauth","year":"2009","unstructured":"Krauth M-T, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711\u201320.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"469_CR49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2015.242","volume":"30","author":"B Peter","year":"2015","unstructured":"Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30:464\u201372.","journal-title":"Leukemia"},{"key":"469_CR50","doi-asserted-by":"crossref","unstructured":"\u2022 DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2017; Long-term follow-up of midostaurin-treated advSM patients demonstrating the potential for long-term responses and continued drug safety profile","DOI":"10.1038\/leu.2017.234"},{"key":"469_CR51","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"\u2022\u2022 Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530\u201341. Registration study of the multikinase\/KIT inhibitor midostaurin in advSM demonstrating high rates of reversion of organ damage, reduction in serum tryptase and BM MC burden, splenomegaly, and improvement in symptom burden\/quality of life.","journal-title":"N Engl J Med"},{"issue":"7","key":"469_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny H-P, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635\u201341.","journal-title":"Leukemia Research"},{"issue":"13","key":"469_CR53","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J. Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013;121:2393\u2013401.","journal-title":"Blood"},{"key":"469_CR54","unstructured":"FDA. Rydapt (midostaurin) capsules [package insert] [Internet]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017 Apr. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf ."},{"issue":"26","key":"469_CR55","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMc1515403","volume":"374","author":"Marie-Olivia Chandesris","year":"2016","unstructured":"Chandesris M-O, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, et al. Midostaurin in advanced systemic Mastocytosis. N Engl J Med. 2016;374:2605\u20137.","journal-title":"New England Journal of Medicine"},{"key":"469_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"130","author":"M Jawhar","year":"2017","unstructured":"\u2022\u2022 Jawhar M, Schwaab J, Naumann N, Horny H-P, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137\u201345. First reported NGS data for midostaurin-treated advSM patients describing molecular patterns of response and relapse.","journal-title":"Blood"},{"key":"469_CR57","first-page":"S788","volume":"102","author":"A Reiter","year":"2017","unstructured":"Reiter A, Kluin-Nelemans HC, George TI, Akin C, DeAngelo DJ, Hermine O, et al. Pooled survival analysis of midostaurin clinical study data (D2201 + A2213) in patients with advanced systemic mastocytosis (AdvSM) compared with historical controls. Haematologica. 2017;102:S788.","journal-title":"Haematologica"},{"issue":"3","key":"469_CR58","doi-asserted-by":"publisher","first-page":"1006-1008.e7","DOI":"10.1016\/j.jaci.2018.06.003","volume":"142","author":"Bjorn van Anrooij","year":"2018","unstructured":"Van Anrooij B, Oude Elberink JNG, Span LF, de Monchy JGR, Rosati S, Mulder AB, Kluin-Nelemans JC. Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial. J Allergy Clin Immunol. 2018. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.003 .","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"469_CR59","doi-asserted-by":"crossref","unstructured":"Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med. 2017;9:eaao1690.","DOI":"10.1126\/scitranslmed.aao1690"},{"key":"469_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2017-05-781278","volume":"130","author":"DA DJ","year":"2017","unstructured":"\u2022\u2022 DJ DA, Quiery AT, Radia D, Drummond MW, Gotlib J, Robinson WA, et al. Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM). Blood. 2017;130:2. Phase I dose-escalation study of the KIT D816V-specific inhibitor avapritinib (BLU-285) in advSM demonstrating high rates of clinical responses and reduction in bone marrow mast cell and KIT D816V allele burden, as well as description of safety\/tolerability and recommended phase II dose.","journal-title":"Blood"},{"key":"469_CR61","doi-asserted-by":"crossref","unstructured":"Schneeweiss MA, Peter B, Blatt K, Berger D, Stefanzl G, Hadzijusufovic E, et al. The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis. Blood. 2016;128:1965\u20135.","DOI":"10.1182\/blood.V128.22.1965.1965"},{"issue":"6","key":"469_CR62","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"K. P. Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126:790\u20137.","journal-title":"Blood"},{"issue":"9","key":"469_CR63","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"Kate J. Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130:1125\u201331.","journal-title":"Blood"},{"key":"469_CR64","doi-asserted-by":"crossref","unstructured":"Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy. Blood Adv. 2017;1:1729\u201338.","DOI":"10.1182\/bloodadvances.2017009530"},{"issue":"2","key":"469_CR65","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"K. V. Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752\u20139.","journal-title":"Blood"},{"key":"469_CR66","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, H\u00f6rmann G, Rix U, Bennett KL, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011;118:1885\u201398.","journal-title":"Blood"},{"key":"469_CR67","unstructured":"Baird JH, Verstovsek S, George TI, Reyes I, Abuel J, Perkins C, et al. Phase 2 study of brentuximab vedotin in patients with advanced systemic mastocytosis. Blood. 2017;130:2909\u20139."},{"key":"469_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","volume":"44","author":"U Borate","year":"2016","unstructured":"Borate U, Mehta A, Reddy V, Tsai M, Josephson N, Schnadig I. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res. 2016;44:25\u201331.","journal-title":"Leuk Res"},{"issue":"8","key":"469_CR69","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/leu.2016.30","volume":"30","author":"I Alvarez-Twose","year":"2016","unstructured":"Alvarez-Twose I, Mart\u00ednez-Barranco P, Gotlib J, Garc\u00eda-Montero A, Morgado JM, Jara-Acevedo M, et al. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia. 2016;30:1753\u20136.","journal-title":"Leukemia"},{"key":"469_CR70","doi-asserted-by":"crossref","unstructured":"Vaes M, Benghiat FS, Hermine O. Targeted treatment options in mastocytosis. Front Med (Lausanne) [Internet]. 2017 [cited 2018 Jan 2];4. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5517467\/ .","DOI":"10.3389\/fmed.2017.00110"},{"issue":"8","key":"469_CR71","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1096\/fj.14-250894","volume":"28","author":"Gregor Hoermann","year":"2014","unstructured":"Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, et al. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J. 2014;28:3540\u201351.","journal-title":"The FASEB Journal"},{"key":"469_CR72","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","volume":"22","author":"C Ustun","year":"2016","unstructured":"\u2022 Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant. 2016;22:1348\u201356. Consensus recommendations on the role of allogeneic HSCT in the treatment of advSM.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"29","key":"469_CR73","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"Celalettin Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264\u201374.","journal-title":"Journal of Clinical Oncology"},{"key":"469_CR74","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1126\/science.1149726","volume":"318","author":"A Czechowicz","year":"2007","unstructured":"Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007;318:1296\u20139.","journal-title":"Science"},{"key":"469_CR75","doi-asserted-by":"publisher","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","volume":"8","author":"A Chhabra","year":"2016","unstructured":"Chhabra A, Ring AM, Weiskopf K, Schnorr PJ, Gordon S, Le AC, et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med. 2016;8:351ra105.","journal-title":"Sci Transl Med"},{"key":"469_CR76","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B Anrooij van","year":"2016","unstructured":"van Anrooij B, Kluin-Nelemans JC, Safy M, Flokstra-de Blok BM, Oude Elberink JN. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71:1585\u201393.","journal-title":"Allergy"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-018-0469-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0469-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0469-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T03:41:17Z","timestamp":1571802077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-018-0469-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s11899-018-0469-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,28]]},"assertion":[{"value":"28 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Gotlib has, or will be serving, as Study Steering Committee Chairman or Co-Chairman of trials involving midostaurin, avapritinib, and DCC-2618 in advanced systemic mastocytosis (AdvSM). His institution received funding for conduct of these clinical trials, as well as brentuximab vedotin, for which he was principal investigator. Dr. Gotlib has also served on advisory boards, received honoraria, and reimbursement for travel expenses from Novartis, Blueprint Medicines, and Deciphera, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}